Ashwagandha and Your Liver: What Health Canada's 2026 Safety Review Means for NHP Licence Holders

Ashwagandha has become one of the most searched supplements in Canada, promoted for stress, sleep and energy. In August 2026, Health Canada added a note of caution. Its completed Summary Safety Review of ashwagandha for oral use concluded that a possible link to liver injury cannot be ruled out. For consumers, that is a headline. For the companies that licence and sell ashwagandha natural health products, it is a compliance signal that should trigger a specific set of actions.

This article explains what the review found, what a Summary Safety Review actually is, and what a licence holder must verify now. It places the Canadian finding in its international context, because the same signal has surfaced in Australia and Europe, and it sets out the post-market obligations that too many companies treat as optional until an inspector or a safety review proves otherwise.

Executive summary

Health Canada completed a Summary Safety Review of oral ashwagandha and found that the evidence was not sufficient to establish a definite link to liver injury, but a possible link could not be ruled out. The department did not order a mandatory label change, confirmed that existing monographs remain appropriate, and said it will continue to monitor the risk. It communicated the finding through the August 2026 Health Product InfoWatch and a public awareness campaign. The signal aligns with earlier action in Australia and a broader pattern of botanical hepatotoxicity communications worldwide.

What Health Canada's ashwagandha safety review found

Health Canada reviewed the risk of hepatotoxicity, meaning liver injury, from the oral use of ashwagandha-containing natural health products. The review did not find sufficient evidence to establish a definite link, but it concluded that a possible link could not be ruled out. Health Canada will continue to monitor the risk and has kept the existing monograph in place.

The finding was published as a Summary Safety Review titled Ashwagandha for Oral Use and disseminated through the Health Product InfoWatch, August 2026 edition, which was issued on 27 August 2026 and recaps items published in July 2026. Health Canada paired the review with a social media campaign so that consumers and healthcare professionals understand that a possible link between oral ashwagandha and liver injury cannot be excluded. Ashwagandha, known botanically as Withania somnifera, is an adaptogen sold widely in capsules, powders, gummies and blended formulas.

The important nuance for industry is what the review did not do. It did not conclude that ashwagandha causes liver injury. It did not remove any product from the market, and it did not require a new warning statement. It did document a safety signal, place it on the public record, and signal continued surveillance. That combination is exactly the situation a well run post-market programme is built to handle.

What is a Summary Safety Review?

A Summary Safety Review is Health Canada's published assessment of a potential safety signal for a marketed health product. It sets out the concern, the evidence Health Canada examined, the conclusion, and any action taken. Reviews can end with no change, a label or monograph update, a risk communication, or a referral toward stronger action such as a recall.

Health Canada opens a review when a signal emerges from adverse reaction reports, published literature, international regulator action, or its own analysis. The department weighs the strength of the evidence, including the number and quality of case reports, biological plausibility, and whether other causes can be excluded. The outcome is graded. A review may find no clear link, a possible link that cannot be ruled out, or a probable or confirmed link. The ashwagandha review landed in the middle category: not proven, not dismissed.

Mechanism	What it is	What it means for a licence holder
Summary Safety Review	A published assessment of a safety signal	Verify alignment, review your evidence, prepare to respond, and monitor for escalation
Product monograph or label safety update	A required change to warnings, contraindications or directions	Implement the wording change and update labels within the timeline set
Recall	Removal or correction of product already on the market	Execute your recall procedure, notify Health Canada, reconcile distribution and report

Understanding where a review sits on that spectrum tells you how urgently to act. A no change outcome, like the one ashwagandha received, still deserves a documented internal response. A label update is mandatory work with a deadline. A recall is a full crisis procedure. Confusing these levels, or ignoring the first because it is not mandatory, is a common and avoidable mistake.

Why the ashwagandha finding matters for licence holders

It matters because a documented safety signal changes your risk position even when no action is ordered. If a consumer reports liver injury, if a retailer asks for your safety file, or if Health Canada requests information, you must be able to show that your product aligns with the current monograph and that your pharmacovigilance system is working. A published review raises the expectation that you already know this.

There is also a commercial dimension. Ashwagandha is a high volume category, and negative headlines move quickly. Buyers, marketplaces and importers increasingly ask suppliers to confirm regulatory status before they will stock or renew. A licence holder who can produce a clean monograph cross check, a current risk assessment and an adverse reaction summary is in a far stronger position than one scrambling to assemble those documents after a customer or regulator asks.

Finally, the finding sits inside a wider trend. Regulators in several countries have issued botanical hepatotoxicity communications in recent years, and ashwagandha is now part of that pattern, much as identity and potency questions have shaped other NHP categories. A signal that is unproven today can strengthen as more case reports accumulate. Companies that treat the 2026 review as an early warning, rather than a non-event, will be ready if the evidence grows.

What NHP licence holders must do now

Take five practical steps: confirm your formulation and claims match the current Health Canada ashwagandha monograph; review your product risk information and labelling; confirm your adverse reaction reporting is active and compliant; test your complaint handling and recall readiness; and assemble a short safety position you can defend if asked. None of this requires a label change today. All of it protects you if the signal escalates.

Start with the monograph. Health Canada's ashwagandha monograph sets out the accepted source material, doses, uses, durations of use and required cautions. Confirm that your licensed product still matches it, that your finished product specifications control identity and that your label reflects the current risk statements. If your product uses a non-monograph combination or claim, your obligation to justify safety is higher, not lower, especially where undeclared or substituted ingredients are a known risk in the botanical supply chain.

Then look at pharmacovigilance. Every NHP licence holder must collect, assess and report adverse reactions. A liver injury report linked to ashwagandha is now a foreseeable event, so your intake, triage and reporting workflow must be able to catch it, code it correctly and file it on time. If you cannot say with confidence when your last adverse reaction summary was prepared, that is the gap to close first. Our overview of how effective the NHP regulations are covers the post-market duties in more depth.

The post-market obligations behind the review

Two frameworks sit behind every safety review. The Natural Health Products Regulations require licence holders to report serious adverse reactions and to keep an annual summary. Since 2023, amendments to the Food and Drugs Act give Health Canada the power to order an NHP recall or a label change when it finds a serious risk to health. Together they mean a safety signal can move from information to enforcement.

Under sections 24 and 25 of the Natural Health Products Regulations, a licence holder must submit a case report for each serious adverse reaction that occurs in Canada within 15 days of becoming aware of it, and for each serious unexpected adverse reaction occurring inside or outside Canada within 15 days. The licence holder must also prepare an annual summary report that critically analyses all adverse reactions, and must be ready to provide it to Health Canada on request. These are not optional records. They are the evidence that your safety system works.

The enforcement backdrop changed in June 2023, when Bill C-47 removed the exemption that had kept natural health products outside Vanessa's Law. Health Canada can now order the recall of an NHP that presents a serious or imminent risk of injury, order a label or package change, and seek penalties that can reach into the millions of dollars for serious non-compliance. A safety signal that today produces only a monograph review can, with more evidence, become the basis for a mandatory action. That is why the right response to the ashwagandha review is preparation, not complacency.

The international picture: Australia and Europe

Canada is not acting alone. Australia's Therapeutic Goods Administration issued a safety advisory on Withania somnifera and a very rare risk of liver injury, and other regulators have flagged botanical liver signals. The convergence matters because international regulator action is itself a trigger that can accelerate a Canadian review or a future label change.

The Therapeutic Goods Administration reported that it had received 12 reports of liver problems in consumers taking Withania somnifera products up to early February 2024, of which seven contained enough information to suggest the herb may have caused the injury and four had no other likely contributing ingredient. The agency signalled that a mandatory label warning was under consideration. For a Canadian licence holder that also exports, an emerging Australian warning statement can create a labelling mismatch that must be managed across markets.

The practical lesson is to watch the whole regulatory field, not just Health Canada. When two or more trusted regulators describe the same signal, the probability of a Canadian monograph or label change rises. Building an international horizon scan into your quality system, so that a foreign advisory or review reaches your regulatory team quickly, is a low cost way to avoid being caught out.

A practical example: what a documented response looks like

Consider a mid-sized company that licences three ashwagandha products. A well run response to the 2026 review takes about a day of focused work and produces a short, dated internal memo that any inspector or customer would find reassuring. The value is not in the length of the document, it is in the fact that the assessment was made, recorded and owned.

The memo confirms that each product still matches the current Health Canada monograph, that certificates of analysis identify the species Withania somnifera, and that the label carries the approved cautions. It records that the adverse reaction procedure was tested against a hypothetical liver injury report and that the annual summary is up to date. It notes that a foreign regulator, the Therapeutic Goods Administration, has flagged the same signal, and that the company will monitor for any Canadian label change. Finally, it names the person responsible and the date of the next review. That single document turns a public safety signal into evidence of a controlled, professional quality system. It is the difference between looking prepared and being prepared, and it is exactly what a gap assessment is designed to produce.

Ashwagandha compliance checklist

Use this checklist to document your response to the 2026 safety review. Keep the completed version in your quality records so you can show a considered assessment if asked.

Confirm each ashwagandha product licence matches the current Health Canada ashwagandha monograph for source material, dose, use and duration.
Verify finished product specifications control identity, and that certificates of analysis confirm the species Withania somnifera.
Review labels and risk information against the current monograph cautions and your approved product licence.
Confirm your adverse reaction intake, assessment and 15 day serious reporting workflow is active and documented.
Locate or prepare your most recent annual adverse reaction summary report.
Test complaint handling and recall readiness with a mock scenario involving a liver injury report.
Set up an international horizon scan for TGA, EMA and other regulator communications on ashwagandha.
Write a one page safety position that summarises your evidence and monograph alignment, ready to share with Health Canada or a customer.

Common mistakes

Treating a no change safety review as a non-event and keeping no internal record of any response.
Assuming the monograph you filed years ago still matches the current Health Canada version without checking.
Relying on a supplier certificate that confirms ashwagandha by common name only, with no species level identity testing.
Having no defined trigger for reviewing products when a foreign regulator issues a safety advisory.
Discovering, only after a complaint, that the annual adverse reaction summary was never prepared.
Marketing non-monograph claims or combinations without a documented safety justification.

Frequently asked questions

Did Health Canada ban or recall ashwagandha?

No. Health Canada completed a Summary Safety Review and found that a possible link to liver injury could not be ruled out, but it did not establish a definite link, did not recall any product, and did not order a new warning. It confirmed the existing monograph remains appropriate and said it will keep monitoring.

Do I need to change my ashwagandha label now?

Not because of this review. Health Canada did not mandate a label change. You should, however, confirm that your current label already matches the approved monograph and product licence, and be ready to update quickly if a future review requires a warning statement.

What is the difference between a Summary Safety Review and a recall?

A Summary Safety Review is an assessment of a safety signal that may or may not lead to action. A recall is the removal or correction of product already on the market. A review can lead to a recall if the evidence is strong enough, but the ashwagandha review did not reach that point.

What are my adverse reaction reporting duties for an NHP?

Under the Natural Health Products Regulations, you must report each serious adverse reaction in Canada within 15 days of awareness, report each serious unexpected reaction inside or outside Canada within 15 days, and prepare an annual summary report analysing all adverse reactions. You must provide that summary to Health Canada on request.

Can Health Canada force a recall of a natural health product?

Yes. Since 2023, amendments to the Food and Drugs Act allow Health Canada to order the recall of a natural health product that presents a serious or imminent risk of injury, and to order a label or package change. Serious non-compliance can also carry substantial penalties.

How does the Australian ashwagandha warning affect Canadian companies?

Australia's Therapeutic Goods Administration has flagged a very rare risk of liver injury with Withania somnifera and signalled a possible label warning. If you sell into both markets, you may face different label requirements, so it is wise to track international action and plan for a harmonised risk statement.

How MFLRC can help

MF License and Regulatory Consultants helps natural health product companies turn a safety signal into a controlled, documented response. We review your product licences and finished product specifications against the current Health Canada ashwagandha monograph, carry out a gap assessment of your labelling and risk information, and build or strengthen the pharmacovigilance and adverse reaction reporting programme that the Natural Health Products Regulations require. Our team also drafts the standard operating procedures for complaint handling, adverse reaction intake and recall readiness that inspectors expect to see, and prepares a defensible safety position you can share with regulators or customers.

Whether you sell a single ashwagandha product or a broad botanical range, we help you close the gaps before Health Canada, a marketplace or a customer asks you to prove your safety position. Explore our natural health product and quality assurance services, or speak with a senior consultant about your specific portfolio.

Book a consultation

Conclusion

Health Canada's 2026 ashwagandha safety review is not a ban, and it is not a recall. It is a documented signal that a possible link to liver injury cannot be ruled out, backed by the power to escalate if the evidence grows. The licence holders who come out of this well will be the ones who treat the review as a prompt to check their monograph alignment, tighten their pharmacovigilance, and prepare a safety position they can defend. That is ordinary good practice made urgent by a specific, public finding. The work is modest. The protection it provides is not.